Teitsson S, Brodtkorb TH, Kurt M, Patel MY, et al. Challenges, considerations, and approaches for developing a cost-effectiveness model for the adjuvant treatment of muscle-invasive urothelial carcinoma: with a spotlight on nivolumab versus placebo. J Med Econ 2024;27:473-481.
PMID: 38385621